Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000401302

Medchemexpress LLC Pumosetrag Hydrochloride | 194093-42-0 | 99.8% | 339.84 | 1 ML
SDP

Catalog No. 5000401302
Encompass_Preferred

Pumosetrag Hydrochloride (MKC-733; DDP-733) is an orally available 5-HT3 partial agonist developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

  • Orally available 5-HT3 partial agonist
  • Developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease
  • Activity profile varies by species and region of the intestine
  • Inhibits responses to ondansetron, confirming action on 5-HT3 receptors
  • Delays liquid gastric emptying, stimulates fasting antroduodenal migrating motor complex activity, and accelerates small intestinal transit

Catalog No. 50-004-01302 Supplier Medchemexpress LLC Supplier No. HY1965010MM/1ML
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Pumosetrag Hydrochloride (MKC-733; DDP-733) is an orally available 5-HT3 partial agonist developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.

  • Orally available 5-HT3 partial agonist
  • Developed for the treatment of irritable bowel syndrome and gastroesophageal reflux disease
  • Activity profile varies by species and region of the intestine
  • Inhibits responses to ondansetron, confirming action on 5-HT3 receptors
  • Delays liquid gastric emptying, stimulates fasting antroduodenal migrating motor complex activity, and accelerates small intestinal transit

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.